Data Update : Zydus Life

Zydus Life US arm buys injection to treat rare paediatric disorder

Zydus Life: Arm, BridgeBio Pharma in pact for BridgeBio Pharma's NULIBRY

Zydus Life: Arm Sentynl to acquire global rights to NULIBRY

Zydus Life: BridgeBio to share development responsibility for NULIBRY

Zydus Life: BridgeBio to get payments, royalties on NULIBRY sales

Zydus Lifesciences Ltd's wholly owned subsidiary in the US, Sentynl Therapeutics Inc, has executed an asset purchase agreement with BridgeBio for Nulibry (Fosdenopterin), a medication used to treat an ultra-rare, life-threatening paediatric genetic disorder, the company said in an exchange filing.

As per the agreement, Sentynl Therapeutics will acquire global rights to Nulibry and be responsible for its manufacture, development and commercialisation worldwide.

Sentynl Therapeutics will provide cash payment on achieving certain regulatory milestones, while BridgeBio will get payments on achieving commercial milestones and tiered royalties on adjusted net sales of Nulibry.

For Opening DP and Trading account, Mutual Fund Investments and Two/Four Wheeler Insurance Renewal, please contact 9831200699 / 8274909974

Exclusive for ANM News Viewers - ANM's Financial & Insurance Related News - To join our group please visit https://www.facebook.com/groups/668263891032421

Source : Eureka

Please register at https://kyc.eurekasecurities.net/home/index/729 for opening Trading and Demat Account.